valproic acid has been researched along with Cardiovascular Diseases in 13 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We included patients who had a diagnosis of bipolar disorder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer treatment." | 3.83 | Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study. ( Geddes, JR; Hayes, JF; King, M; Marston, L; Osborn, DP; Walters, K, 2016) |
| "Although mania defines bipolar I disorder, depressive episodes and symptoms dominate the longitudinal course of, and disproportionately account for morbidity and mortality in, bipolar disorders." | 2.66 | Bipolar disorders. ( Berk, M; Brietzke, E; Goldstein, BI; Kessing, LV; López-Jaramillo, C; Majeed, A; Malhi, GS; Mansur, RB; McIntyre, RS; Nierenberg, AA; Rosenblat, JD; Vieta, E; Vinberg, M; Young, AH, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Pedro Ferreira, J | 1 |
| Pitt, B | 1 |
| Zannad, F | 1 |
| Akbar, N | 1 |
| Anum, H | 1 |
| Razzaq, SS | 1 |
| Salim, A | 1 |
| Usman, S | 1 |
| Haneef, K | 1 |
| McIntyre, RS | 1 |
| Berk, M | 1 |
| Brietzke, E | 1 |
| Goldstein, BI | 1 |
| López-Jaramillo, C | 1 |
| Kessing, LV | 1 |
| Malhi, GS | 1 |
| Nierenberg, AA | 1 |
| Rosenblat, JD | 1 |
| Majeed, A | 1 |
| Vieta, E | 1 |
| Vinberg, M | 1 |
| Young, AH | 1 |
| Mansur, RB | 1 |
| Holder, SD | 1 |
| Patel, BM | 1 |
| Raghunathan, S | 1 |
| Porwal, U | 1 |
| Harit, D | 1 |
| Aggarwal, A | 1 |
| Kalra, S | 1 |
| Chhillar, N | 1 |
| Hayes, JF | 1 |
| Marston, L | 1 |
| Walters, K | 1 |
| Geddes, JR | 1 |
| King, M | 1 |
| Osborn, DP | 1 |
| Verrotti, A | 1 |
| Manco, R | 1 |
| Agostinelli, S | 1 |
| Coppola, G | 1 |
| Chiarelli, F | 1 |
| Swartz, HA | 1 |
| Fagiolini, A | 1 |
| Ferrari, R | 1 |
| Merli, E | 1 |
| Cicchitelli, G | 1 |
| Mele, D | 1 |
| Fucili, A | 1 |
| Ceconi, C | 1 |
| Kilbourne, AM | 1 |
| Post, EP | 1 |
| Bauer, MS | 1 |
| Zeber, JE | 1 |
| Copeland, LA | 1 |
| Good, CB | 1 |
| Pincus, HA | 1 |
| Zarate, CA | 1 |
| Baldessarini, RJ | 1 |
| Siegel, AJ | 1 |
| Nakamura, A | 1 |
| McDonald, J | 1 |
| Muir-Hutchinson, LA | 1 |
| Cherkerzian, T | 1 |
| Tohen, M | 1 |
| Isojärvi, JI | 1 |
| Taubøll, E | 1 |
| Pakarinen, AJ | 1 |
| van Parys, J | 1 |
| Rättyä, J | 1 |
| Harbo, HF | 1 |
| Dale, PO | 1 |
| Fauser, BC | 1 |
| Gjerstad, L | 1 |
| Koivunen, R | 1 |
| Knip, M | 1 |
| Tapanainen, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for valproic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Histone Deacetylase Inhibitors; Humans; Longevity; V | 2021 |
Bipolar disorders.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; B | 2020 |
Psychotic and Bipolar Disorders: Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Cardiovascular Diseases; Chronic Pain; Comorbidity; Family Pract | 2017 |
Cardiovascular disease and bipolar disorder: risk and clinical implications.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Cardiovascular Diseases; | 2012 |
Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.
Topics: Cardiotonic Agents; Cardiovascular Diseases; Carnitine; Humans; Kidney Failure, Chronic; Liver; Myoc | 2004 |
8 other studies available for valproic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Ascorbic acid and salvianolic acid B enhance the valproic acid and 5-azacytidinemediated cardiac differentiation of mesenchymal stem cells.
Topics: Ascorbic Acid; Azacitidine; Cardiovascular Diseases; Cell Differentiation; Cells, Cultured; Humans; | 2023 |
Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Experimen | 2014 |
Effect of Carbamazepine and Valproate Monotherapy on Cardiovascular Risks in Epileptic Children.
Topics: Anticonvulsants; Apolipoproteins A; Apolipoproteins B; Blood Chemical Analysis; Carbamazepine; Cardi | 2015 |
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cardiovascular Diseases; Chemical an | 2016 |
The metabolic syndrome in overweight epileptic patients treated with valproic acid.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Cardiovascular Diseases; Child; Comorbidity; Dyslipide | 2010 |
Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Cardiovascular Diseases; Drug Monitori | 2007 |
Risperidone in the elderly: a pharmacoepidemiologic study.
Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity; | 1997 |
Altered ovarian function and cardiovascular risk factors in valproate-treated women.
Topics: Adult; Analysis of Variance; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Case-Control S | 2001 |